[go: up one dir, main page]

WO2004106935A3 - Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur 103 couples aux proteines g (gpr103) - Google Patents

Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur 103 couples aux proteines g (gpr103) Download PDF

Info

Publication number
WO2004106935A3
WO2004106935A3 PCT/EP2004/005257 EP2004005257W WO2004106935A3 WO 2004106935 A3 WO2004106935 A3 WO 2004106935A3 EP 2004005257 W EP2004005257 W EP 2004005257W WO 2004106935 A3 WO2004106935 A3 WO 2004106935A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
gpr103
diseases
therapeutics
diagnostics
Prior art date
Application number
PCT/EP2004/005257
Other languages
English (en)
Other versions
WO2004106935A2 (fr
Inventor
Stefan Golz
Ulf Brueggemeier
Holger Summer
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Holger Summer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Holger Summer filed Critical Bayer Healthcare Ag
Publication of WO2004106935A2 publication Critical patent/WO2004106935A2/fr
Publication of WO2004106935A3 publication Critical patent/WO2004106935A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4719—G-proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention se rapporte au récepteur GPR103 humain qui est associé aux troubles cardio-vasculaires, aux troubles hormonaux et du système endocrinien, aux maladies gastro-intestinales et hépatiques, aux maladies métaboliques, aux maladies inflammatoires, aux troubles neurologiques, aux troubles cancéreux et aux troubles urologiques. L'invention se rapporte également à des analyses permettant l'identification de composés utiles pour le traitement ou la prévention de troubles cardio-vasculaires, de troubles hormonaux et du système endocrinien, de maladies gastrointestinales et hépatiques, de maladies métaboliques, de maladies inflammatoires, de troubles neurologiques, de troubles cancéreux et de troubles urologiques. L'invention se rapporte également à des composés qui se lient au récepteur GPR103 et/ou qui activent ou inhibent l'activité de ce récepteur ainsi qu'à des compositions pharmaceutiques comportant ces composés.
PCT/EP2004/005257 2003-05-27 2004-05-15 Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur 103 couples aux proteines g (gpr103) WO2004106935A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03011878.0 2003-05-27
EP03011878 2003-05-27

Publications (2)

Publication Number Publication Date
WO2004106935A2 WO2004106935A2 (fr) 2004-12-09
WO2004106935A3 true WO2004106935A3 (fr) 2008-01-17

Family

ID=33483889

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/005257 WO2004106935A2 (fr) 2003-05-27 2004-05-15 Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur 103 couples aux proteines g (gpr103)

Country Status (1)

Country Link
WO (1) WO2004106935A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006039256A1 (fr) * 2004-09-29 2006-04-13 Glaxo Group Limited Utilisation d'agonistes du gpr103 pour moduler le comportement alimentaire
GB201512733D0 (en) * 2015-07-20 2015-08-26 Genagon Therapeutics Ab Therapeutic agents for treating conditions associated with elevated GDF15
GB201700567D0 (en) 2017-01-12 2017-03-01 Genagon Therapeutics Ab Therapeutic agents

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000011015A1 (fr) * 1998-08-24 2000-03-02 Alphagene, Inc. Proteines secretees et polynucleotides codant pour ces proteines
WO2001057215A2 (fr) * 2000-02-07 2001-08-09 Curagen Corporation Nouveaux polypeptides et acides nucleiques codant ces derniers
WO2002036632A2 (fr) * 2000-11-02 2002-05-10 Curagen Corporation Nouveaux polymorphismes de nucleotide simple pour polypeptides de type recepteur olfactif et acides nucleiques les codant
EP1207201A1 (fr) * 1999-08-27 2002-05-22 Takeda Chemical Industries, Ltd. Proteine recepteur couplee a une proteine g et adn correspondant
WO2002042458A2 (fr) * 2000-11-22 2002-05-30 Tularik Inc. Nouveaux recepteurs
WO2002057453A2 (fr) * 2000-12-19 2002-07-25 Curagen Corporation Polypeptides et acides nucleiques codant ces derniers
WO2002061087A2 (fr) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Peptides antigeniques destines a des recepteurs couples a la proteine g (gpcr), anticorps s'y rapportant, et systeme d'identification desdits peptides antigeniques
WO2002068649A2 (fr) * 2001-01-31 2002-09-06 Curagen Corporation Proteines et acides nucleiques les codant

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000011015A1 (fr) * 1998-08-24 2000-03-02 Alphagene, Inc. Proteines secretees et polynucleotides codant pour ces proteines
EP1207201A1 (fr) * 1999-08-27 2002-05-22 Takeda Chemical Industries, Ltd. Proteine recepteur couplee a une proteine g et adn correspondant
WO2001057215A2 (fr) * 2000-02-07 2001-08-09 Curagen Corporation Nouveaux polypeptides et acides nucleiques codant ces derniers
WO2002036632A2 (fr) * 2000-11-02 2002-05-10 Curagen Corporation Nouveaux polymorphismes de nucleotide simple pour polypeptides de type recepteur olfactif et acides nucleiques les codant
WO2002042458A2 (fr) * 2000-11-22 2002-05-30 Tularik Inc. Nouveaux recepteurs
WO2002057453A2 (fr) * 2000-12-19 2002-07-25 Curagen Corporation Polypeptides et acides nucleiques codant ces derniers
WO2002061087A2 (fr) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Peptides antigeniques destines a des recepteurs couples a la proteine g (gpcr), anticorps s'y rapportant, et systeme d'identification desdits peptides antigeniques
WO2002068649A2 (fr) * 2001-01-31 2002-09-06 Curagen Corporation Proteines et acides nucleiques les codant

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JIANG YING ET AL: "Identification and characterization of a novel RF-amide peptide ligand for orphan G-protein-coupled receptor SP9155", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 278, no. 30, 25 July 2003 (2003-07-25), pages 27652 - 27657, XP002267776, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO2004106935A2 (fr) 2004-12-09

Similar Documents

Publication Publication Date Title
WO2005075665A3 (fr) Agents diagnostiques et therapeutiques pour des maladies associees a la kallikreine plasmatique (klkb1)
WO2004104215A3 (fr) Approches diagnostiques et therapeutiques des maladies associees a la dipeptidylpeptidase 7 (dpp7)
WO2005106492A3 (fr) Diagnostic et traitement therapeutique des maladies associees au recepteur 3 de la chimiokine c-c (ccr3)
WO2005040828A3 (fr) Agents de diagnostic et de traitement des maladies associees au recepteur 49 couple aux proteines g (gpr49)
WO2004099782A3 (fr) Approche diagnostique et therapeutique des maladies associees au recepteur gpr39 (gpr39) couple a une proteine g
WO2005050225A3 (fr) Outils de diagnostic et de traitement de maladies associees au recepteur 84 couple aux proteines g (gpr84)
WO2004106935A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur 103 couples aux proteines g (gpr103)
WO2005095973A3 (fr) Methodes diagnostiques et therapeutiques pour des maladies associees au recepteur 54 couple a la proteine g (gpr54)
WO2005040211A3 (fr) Composes destines au diagnostic et au traitement de maladies associees au recepteur 1 couple aux proteines g (gpr1)
WO2005040825A3 (fr) Diagnostics et therapeutiques pour maladies liees au recepteur 20 couple a la proteine g (gpr20)
WO2005040829A3 (fr) Agents de diagnostic et de traitement des maladies associees au recepteur 17 couple aux proteines g (gpr17)
WO2005059546A3 (fr) Diagnostics et therapeutique destines au traitement de maladies associees au recepteur couple aux proteines g 35 (gpr35)
WO2004099783A3 (fr) Diagnostics et therapies destines a des maladies associees au recepteur ltb4 (ltb4) couple a la proteine g
WO2004086034A3 (fr) Agents diagnostiques et therapeutiques pour maladies associees au recepteur adenosine a3 couple a la proteine g (adora3)
WO2004099781A3 (fr) Approches diagnostique et therapeutique des maladies associees au recepteur rdc1 (rdc1) couple a une proteine g
WO2004082571A3 (fr) Diagnostics et therapies pour maladies associees au recepteur 86 couple a la proteine g (gpr86)
WO2004081563A3 (fr) Moyens de diagnostic et therapeutiques pour des maladies associees a la phosphodiesterase 1a (pde1a)
WO2005040790A3 (fr) Diagnostics et therapeutiques pour maladies liees au recepteur 75 couple a la proteine g (gpr75)
WO2005118840A3 (fr) Elements diagnostiques therapeutiques pour des maladies associees a la kallikreine 10 (klk10)
WO2005059504A3 (fr) Diagnostics et therapeutique destines au traitement de maladies associees au recepteur couple aux proteines g gpr34 (gpr34)
WO2005040824A3 (fr) Diagnostics et therapeutiques pour maladies liees au recepteur 24 couple a la proteine g (gpr24)
WO2005003779A3 (fr) Diagnostics et traitements therapeutiques des maladies associees au recepteur 3 couple a une proteine g specifique aux neurones sensoriels (snsr3)
WO2005095984A3 (fr) Compositions diagnostiques et therapeutiques pour des maladies associees au recepteur adrenergique alpha 2a couple a la proteine g (adra2a)
WO2004099772A3 (fr) Methodes diagnostiques et therapeutiques pour les maladies associees au recepteur agtr1a couple aux proteines g (agtr1a)
WO2004099248A3 (fr) Produits de diagnostic et de traitement de maladies associees au recepteur agtr2 couple aux proteines g (agtr2)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase